Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study

The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT₃ receptors, <i>in vitro</i>

Erik H.F. Wong, Robin D. Clark, Edward Leung et al. · British Journal of Pharmacology · 1995 · 170 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Are all 5-HT3 receptor antagonists the same?

Paul Andrews, Pritiranjan Bhandari, Philip T. Davey et al. · European Journal of Cancer · 1992 · 133 citations

Medicine, Pharmacology, Pharmacotherapy +12

Antiemetic guidelines: creating a more practical treatment approach

Jim M. Koeller, Matti Aapro, Richard J. Gralla et al. · Supportive Care in Cancer · 2002 · 111 citations

Pharmacy, Pharmacotherapy, Clinical Medicine +12

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study

C. Seynaeve, Jan C. Schuller, K. Buser et al. · British Journal of Cancer · 1992 · 102 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.

Thomas Beck, Paul J. Hesketh, Stefan Madajewicz et al. · Journal of Clinical Oncology · 1992 · 101 citations

Medicine, Pharmacology, Pharmacotherapy +17